Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Why Is It Important to Look at Cross-Reactivity Among Beta-Lactams?

JUL 12, 2017 | CONTAGION® EDITORIAL STAFF


Meghan Jeffres, PharmD, assistant professor in the Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy, explains the importance of discussing cross-reactivity among beta-lactams.
 
Interview Transcript (slightly modified for readability)
 
“The reason we are discussing cross-reactivity among beta-lactams and why this has become such a ‘hot-button’ issue is that the number of people labeled as penicillin-allergic in the United States is anywhere between 10% and 15%. We think that with this particular group—because they are labeled as penicillin-allergic—physicians and the prescribers avoid using beta-lactams.
 
When you avoid using beta-lactams, you increase the use of vancomycin and flouroquinolones. The use of those secondary antibiotics increases cost, increases super infections, and decreases clinical outcomes. They are inferior to beta-lactams.
 
Therefore, we want to decrease the fear of using beta-lactams in patients that are labeled as penicillin-allergic, [and this is why] we are spending a lot of time talking about cross-reactivity in general versus cross-reactivity specifically.”
 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x